Independent expert panel to begin mental health review

NSW Health, 22 May 2017
“Five mental health experts with wide reaching clinical and lived experience will join NSW Chief Psychiatrist Dr Murray Wright to begin a review of the practice of seclusion, restraint and observations across the NSW mental health system. Health Minister Brad Hazzard and Mental Health Minister Tanya Davies confirmed the review will consider whether existing legislation, policy, clinical governance and practice standards are consistent with national standards, international best practice and the expectations of patients and the community.”
Find media release here.

Alzheimer’s Deaths Jump 55 Percent: CDC

WebMD, 25 May 2017
Author: Steven Reinberg
“As more baby boomers age, deaths from Alzheimer’s disease have jumped 55 percent, and in a quarter of those cases the heavy burden of caregiving has fallen on loved ones, U.S. health officials report. “Alzheimer’s disease is a public health problem that affects not only people with Alzheimer’s disease, but also the people who provide care to them, which is often family members,” said report author Christopher Taylor.”
Find article here.

The Ethics of Clinical Trials Research in Severe Mood Disorders

Bioethics. May 2017. doi:10.1111/bioe.12349
Authors: Nugent, A. C., Miller, F. G., Henter, I. D. and Zarate, C. A.
“Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are highly prevalent, frequently disabling, and sometimes deadly. Additional research and more effective medications are desperately needed, but clinical trials research in mood disorders is fraught with ethical issues. Although many authors have discussed these issues, most do so from a theoretical viewpoint. This manuscript uses available empirical data to inform a discussion of the primary ethical issues raised in mood disorders research.”
Find article here.

GSK must pay $3 million in generic Paxil suicide lawsuit: U.S. jury

Reuters, 20 April 2017
Authors: Nate Raymond, Barbara Grzincic
“GlaxoSmithKline(GSK.L) must pay $3 million to a woman who sued the drug company over the death of her husband, a lawyer who committed suicide after taking a generic version of the antidepressant Paxil, a U.S. jury said on Thursday. A federal judge allowed the victim’s wife to proceed against GSK because it controlled the drug’s design and label, which applied to both the brand-name and generic versions of the drug.”
Find article here.